表紙
市場調查報告書

肺炎治療藥的開發平台分析

Pneumonia Drug Development Pipeline Review, 2017

出版商 GlobalData 商品編碼 564940
出版日期 內容資訊 英文 123 Pages
訂單完成後即時交付
價格
肺炎治療藥的開發平台分析 Pneumonia Drug Development Pipeline Review, 2017
出版日期: 2017年09月26日內容資訊: 英文 123 Pages
簡介

本報告提供各種感染途徑的肺炎 (社區肺炎性肺炎 (CAP)/院內感染性肺炎 (HAP)/人工呼吸器相關肺炎 (VAP)的治療藥臨床實驗·開發趨勢)相關分析,提供疾病概要,迄今治療藥的開發·上市情形,現在臨床實驗中/審查中的主要開發中產品一覽,暫停中·已中止計劃的概要,今後臨床實驗的方向性和實現預測等相關調查。

第1章 目錄

第2章 簡介

  • 分析範圍
  • 社區肺炎性肺炎:概要
  • 院內感染性肺炎:概要
  • 人工呼吸器相關肺炎:概要

第3章 治療藥的開發

  • 社區型肺炎
  • 院內肺炎 (HAP)
  • 人工呼吸器相關肺炎 (VAP)

第4章 治療藥的評估

  • 社區型肺炎
  • 院內肺炎
  • 人工呼吸器相關肺炎

第5章 參與治療藥開發的的企業

  • 社區型肺炎
  • 院內肺炎
  • 人工呼吸器相關肺炎

第6章 現在暫停中的計劃

  • 社區型肺炎
  • 院內肺炎
  • 人工呼吸器相關肺炎

第7章 開發中止的計劃

  • 社區型肺炎
  • 院內肺炎
  • 人工呼吸器相關肺炎

第8章 產品開發的里程碑

  • 社區型肺炎
  • 院內肺炎
  • 人工呼吸器相關肺炎

第9章 附錄

圖表一覽

目錄
Product Code: GBIHC021IDB

Executive Summary:

Community acquired pneumonia refers to pneumonia contracted by a person who has had little contact with the healthcare system. There are a total of 20 products in development for this indication, by 17 companies. Key companies operating in this pipeline space include TaiGen Biotechnology and Merck.

Hospital acquired pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48-72 hours after being admitted, usually caused by a bacterial infection. There are a total of 39 products in development for this indication, by 29 companies. Key companies operating in this pipeline space include Aridis Pharmaceuticals, Wockhardt, AstraZeneca and Merck.

Finally, Ventilator-associated pneumonia is characterized by age-related hyperplasia of the prostate gland (with or without glandular enlargement), lower urinary tract symptoms and bladder flow obstruction. There are a total of 34 products in development for this indication, by 27 companies. Key companies operating in this pipeline space include Aridis Pharmaceuticals, AstraZeneca, Merck and Polyphor.

The most common targets within community acquired pneumonia are DNA gyrase, DNA topoisomerase and ribosomal RNA, common targets of antibiotics. Hospital acquired and ventilator associated pneumonia share many of the same targets and are most frequently targeted towards beta lactamase and ribosomal RNA, also common targets of antibiotic treatments and closely reflecting the current treatment landscape of these diseases.

The report,"Pneumonia Drug Development Pipeline Review, 2017" provides an overview of the pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Community Acquired Pneumonia, Hospital Acquired Pneumonia and Ventilator Associated Pneumonia and features dormant and discontinued projects.

Scope:

  • Which companies are the most active within the pipeline for pneumonia therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of pneumonia?

Reasons to buy:

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Pneumonia Report Coverage
  • 2.2. Community Acquired Pneumonia. Overview
  • 2.3. Hospital Acquired Pneumonia (HAP). Overview
  • 2.4. Ventilator Associated Pneumonia (VAP). Overview

3. Therapeutics Development

  • 3.1. Community Acquired Pneumonia
  • 3.2. Hospital Acquired Pneumonia (HAP)
  • 3.3. Ventilator Associated Pneumonia (VAP)

4. Therapeutics Assessment

  • 4.1. Community Acquired Pneumonia
  • 4.2. Hospital Acquired Pneumonia (HAP)
  • 4.3. Ventilator Associated Pneumonia (VAP)

5. Companies Involved in Therapeutics Development

  • 5.1. Community Acquired Pneumonia
  • 5.2. Hospital Acquired Pneumonia (HAP)
  • 5.3. Ventilator Associated Pneumonia (VAP)

6. Dormant Projects

  • 6.1. Community Acquired Pneumonia
  • 6.2. Hospital Acquired Pneumonia (HAP)
  • 6.3. Ventilator Associated Pneumonia (VAP)

7. Discontinued Products

  • 7.1. Community Acquired Pneumonia
  • 7.2. Hospital Acquired Pneumonia (HAP)
  • 7.3. Ventilator Associated Pneumonia (VAP)

8. Product Development Milestones

  • 8.1. Community Acquired Pneumonia
  • 8.2. Hospital Acquired Pneumonia (HAP)
  • 8.3. Ventilator Associated Pneumonia (VAP)

9. Appendix

  • 9.1. Methodology
  • 9.2. Coverage
  • 9.3. Secondary Research
  • 9.4. Primary Research
  • 9.5. Expert Panel Validation
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Community Acquired Pneumonia
  • Table 2: Number of Products under Development by Companies Community Acquired Pneumonia
  • Table 3: Products under Development by Companies Community Acquired Pneumonia
  • Table 4: Number of Products under Development for Hospital Acquired Pneumonia (HAP)
  • Table 5: Number of Products under Development by Companies Hospital Acquired Pneumonia (HAP)
  • Table 6: Products under Development by Companies Hospital Acquired Pneumonia (HAP)
  • Table 7: Number of Products under Development for Ventilator Associated Pneumonia (VAP)
  • Table 8: Number of Products under Development by Companies Ventilator Associated Pneumonia (VAP)
  • Table 9: Products under Development by Companies Ventilator Associated Pneumonia (VAP)
  • Table 10: Number of Products by Stage and Target Community Acquired Pneumonia
  • Table 11: Number of Products by Stage and Mechanism of Action Community Acquired Pneumonia
  • Table 12: Number of Products by Stage and Route of Administration Community Acquired Pneumonia
  • Table 13: Number of Products by Stage and Molecule Type Community Acquired Pneumonia
  • Table 14: Number of Products by Stage and Target Hospital Acquired Pneumonia (HAP)
  • Table 15: Number of Products by Stage and Mechanism of Action Hospital Acquired Pneumonia (HAP)
  • Table 16: Number of Products by Stage and Route of Administration Hospital Acquired Pneumonia (HAP)
  • Table 17: Number of Products by Stage and Molecule Type Hospital Acquired Pneumonia (HAP)
  • Table 18: Number of Products by Stage and Target Ventilator Associated Pneumonia (VAP)
  • Table 19: Number of Products by Stage and Mechanism of Action Ventilator Associated Pneumonia (VAP)
  • Table 20: Number of Products by Stage and Route of Administration Ventilator Associated Pneumonia (VAP)
  • Table 21: Number of Products by Stage and Molecule Type Ventilator Associated Pneumonia (VAP)
  • Table 22: Community Acquired Pneumonia - Pipeline by Aridis Pharmaceuticals LLC
  • Table 23: Community Acquired Pneumonia - Pipeline by Biotest AG
  • Table 24: Community Acquired Pneumonia - Pipeline by InflaRx GmbH
  • Table 25: Community Acquired Pneumonia - Pipeline by ioGenetics Inc
  • Table 26: Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd
  • Table 27: Community Acquired Pneumonia - Pipeline by Melinta Therapeutics Inc
  • Table 28: Community Acquired Pneumonia - Pipeline by Merck & Co Inc
  • Table 29: Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG
  • Table 30: Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals Inc
  • Table 31: Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co Ltd
  • Table 32: Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Ltd
  • Table 33: Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc
  • Table 34: Community Acquired Pneumonia - Pipeline by TiGenix NV
  • Table 35: Community Acquired Pneumonia - Pipeline by Wockhardt Ltd
  • Table 36: Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc
  • Table 37: Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS
  • Table 38: Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC
  • Table 39: Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc
  • Table 40: Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG
  • Table 41: Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp
  • Table 42: Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd
  • Table 43: Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd
  • Table 44: Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc
  • Table 45: Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC
  • Table 46: Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd
  • Table 47: Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc
  • Table 48: Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc
  • Table 49: Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc
  • Table 50: Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG
  • Table 51: Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor Ltd
  • Table 52: Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH
  • Table 53: Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd
  • Table 54: Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc
  • Table 55: Hospital Acquired Pneumonia (HAP) - Pipeline by The Medicines Company
  • Table 56: Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc
  • Table 57: Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd
  • Table 58: Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc
  • Table 59: Ventilator Associated Pneumonia (VAP) - Pipeline by Achaogen Inc
  • Table 60: Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS
  • Table 61: Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals LLC
  • Table 62: Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc
  • Table 63: Ventilator Associated Pneumonia (VAP) - Pipeline by Bayer AG
  • Table 64: Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp
  • Table 65: Ventilator Associated Pneumonia (VAP) - Pipeline by Destiny Pharma Ltd
  • Table 66: Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd
  • Table 67: Ventilator Associated Pneumonia (VAP) - Pipeline by Lakewood-Amedex Inc
  • Table 68: Ventilator Associated Pneumonia (VAP) - Pipeline by MedImmune LLC
  • Table 69: Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co Ltd
  • Table 70: Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co Inc
  • Table 71: Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc
  • Table 72: Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics AG
  • Table 73: Ventilator Associated Pneumonia (VAP) - Pipeline by Polyphor Ltd
  • Table 74: Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co Ltd
  • Table 75: Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc
  • Table 76: Ventilator Associated Pneumonia (VAP) - Pipeline by The Medicines Company
  • Table 77: Ventilator Associated Pneumonia (VAP) - Pipeline by Theravance Biopharma Inc
  • Table 78: Ventilator Associated Pneumonia (VAP) - Pipeline by Wockhardt Ltd
  • Table 79: Ventilator Associated Pneumonia (VAP) - Pipeline by Zavante Therapeutics Inc
  • Table 80: Community Acquired Pneumonia - Dormant Projects
  • Table 81: Hospital Acquired Pneumonia (HAP) - Dormant Projects
  • Table 82: Ventilator Associated Pneumonia (VAP) - Dormant Projects
  • Table 83: Community Acquired Pneumonia - Discontinued Products
  • Table 84: Hospital Acquired Pneumonia (HAP) - Discontinued Products
  • Table 85: Ventilator Associated Pneumonia (VAP) - Discontinued Products

List of Figures

  • Figure 1: Number of Products under Development for Community Acquired Pneumonia
  • Figure 2: Number of Products under Development by Companies Community Acquired Pneumonia
  • Figure 3: Number of Products under Development for Hospital Acquired Pneumonia (HAP)
  • Figure 4: Number of Products under Development by Companies Hospital Acquired Pneumonia (HAP)
  • Figure 5: Number of Products under Development for Ventilator Associated Pneumonia (VAP)
  • Figure 6: Number of Products under Development by Companies Ventilator Associated Pneumonia (VAP)
  • Figure 7: Number of Products by Targets Community Acquired Pneumonia
  • Figure 8: Number of Products by Stage and Targets Community Acquired Pneumonia
  • Figure 9: Number of Products by Mechanism of Actions Community Acquired Pneumonia
  • Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions Community Acquired Pneumonia
  • Figure 11: Number of Products by Routes of Administration Community Acquired Pneumonia
  • Figure 12: Number of Products by Stage and Routes of Administration Community Acquired Pneumonia
  • Figure 13: Number of Products by Molecule Types Community Acquired Pneumonia
  • Figure 14: Number of Products by Stage and Molecule Types Community Acquired Pneumonia
  • Figure 15: Number of Products by Top 10 Targets Hospital Acquired Pneumonia (HAP)
  • Figure 16: Number of Products by Stage and Top 10 Targets Hospital Acquired Pneumonia (HAP)
  • Figure 17: Number of Products by Top 10 Mechanism of Actions Hospital Acquired Pneumonia (HAP)
  • Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions Hospital Acquired Pneumonia (HAP)
  • Figure 19: Number of Products by Routes of Administration Hospital Acquired Pneumonia (HAP)
  • Figure 20: Number of Products by Stage and Routes of Administration Hospital Acquired Pneumonia (HAP)
  • Figure 21: Number of Products by Molecule Types Hospital Acquired Pneumonia (HAP)
  • Figure 22: Number of Products by Stage and Molecule Types Hospital Acquired Pneumonia (HAP)
  • Figure 23: Number of Products by Top 10 Targets Ventilator Associated Pneumonia (VAP)
  • Figure 24: Number of Products by Stage and Top 10 Targets Ventilator Associated Pneumonia (VAP)
  • Figure 25: Number of Products by Top 10 Mechanism of Actions Ventilator Associated Pneumonia (VAP)
  • Figure 26: Number of Products by Stage and Top 10 Mechanism of Actions Ventilator Associated Pneumonia (VAP)
  • Figure 27: Number of Products by Top 10 Routes of Administration Ventilator Associated Pneumonia (VAP)
  • Figure 28: Number of Products by Stage and Top 10 Routes of Administration Ventilator Associated Pneumonia (VAP)
  • Figure 29: Number of Products by Molecule Types Ventilator Associated Pneumonia (VAP)
  • Figure 30: Number of Products by Stage and Molecule Types Ventilator Associated Pneumonia (VAP)